IP Library Granted Patent US 9,314,441
Granted Patent B2
US 9,314,441 · App. 13/647,816 · Granted Apr 19, 2016

Two phase pharmaceutical delivery system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,314,441
App. No.
13/647,816
Granted
Apr 19, 2016
Kind
B2
Abstract

A bi-phasic pharmaceutical composition for oral administration including one or more solid active ingredient containing particles dispersed within a semi-solid carrier formulation. The solid particles include a coating with pH-triggered drug release properties and the semi-solid carrier formulation is formulated at a pH that is different than the pH at which the active ingredient release properties of the coating are triggered. Also described is a delivery system for delivery of the bi-phasic pharmaceutical composition including the bi-phasic pharmaceutical composition described above and a dispenser pouch formed from flexible laminate sheets. Further, a process for manufacturing the two-phase pharmaceutical delivery system is described including the filling the bi-phasic pharmaceutical composition into flexible dispenser pouches, which allows the patient to squeeze and dispense the contents of the package directly into the oral cavity.

Claims (33)

1. A pharmaceutical composition for oral administration comprising:

a semi-solid hydrogel having a water content of at least 20% by weight, based on the total weight of the hydrogel, said hydrogel is a viscoelastic gel having an elastic modulus which is measured at 20° C. of 0.05 kPa to 500 kPa and which is prepared by heating an aqueous suspension of a hydratable polymeric material to induce formation of a liquid sol, followed by cooling the sol to induce gelling,

a plurality of coated active ingredient containing particles dispersed in said hydrogel, wherein less than 0.1 wt % of the active ingredient is detectable in the hydrogel one month after the preparation of the composition,

at least one coating of said particles is triggered to disintegrate or dissolve by exposure to a particular pH range as a result of which the active ingredient is released,

the hydrogel having a pH sufficiently different from the pH that triggers disintegration or dissolution of the at least one coating of the particles so as to prevent the release of the active ingredient from the particles into the hydrogel,

wherein the hydrogel comprises a buffer system, and

the at least one coating consists of: a) an ionic polymer; or b) non-ionic material selected from the group consisting of lipids, waxes, fats, fatty acids, mono-, di- and triglycerides, acetylated mono- and diglycerides, beeswax, and carnauba wax; and optionally c) at least one selected from the group consisting of pH modifiers, rheological modifiers, solvents, cross-linking agents, glidants, anti-tackifying agents, pigments, dyes, emulsifiers, stabilizers, flavours, sweeteners, and permeability enhancers.

2. The pharmaceutical composition as claimed in claim 1 , wherein the pH of the hydrogel differs from the pH that triggers disintegration or dissolution of the at least one coating of the particles by at least 2.0.

3. The pharmaceutical composition as claimed in claim 1 , wherein the pH of the hydrogel differs from the pH that triggers disintegration or dissolution of the at least one coating of the particles by at least 3.0.

4. The pharmaceutical composition as claimed in claim 1 , wherein the at least one coating is an ionic polymer.

5. The pharmaceutical composition as claimed in claim 4 , wherein the ionic polymer is a cationic polymer.

6. The pharmaceutical composition as claimed in claim 4 , wherein the ionic polymer is an anionic polymer.

7. The pharmaceutical composition as claimed in claim 6 , wherein the at least one coating on said particles is an enteric coating.

8. The pharmaceutical composition as claimed in claim 1 , wherein the buffer system maintains the pH of the hydrogel at a pH of about 5 or less.

9. The pharmaceutical composition as claimed in claim 1 , wherein the buffer system maintains the pH of the hydrogel at a pH of about 5.5-8.

10. The pharmaceutical composition as claimed in claim 1 , wherein the hydrogel has a water content of from about 25% to about 90% by weight, based on the total weight of the hydrogel composition.

11. The pharmaceutical composition as claimed in claim 1 , wherein the at least one coating on said particles is insoluble or only slightly soluble in water.

12. The pharmaceutical composition as claimed in claim 1 , wherein the hydrogel comprises at least one active ingredient which may be the same or different from the active ingredient of the coated particles.

13. The pharmaceutical composition as claimed in claim 1 , wherein the hydrogel is a viscoelastic gel having an elastic modulus which is measured at 20° C. of 0.5 kPa to 50 kPa.

14. A delivery system for the oral administration of a bi-phasic pharmaceutical composition comprising:

a pharmaceutical composition comprising:

a semi-solid hydrogel having a water content of at least 20% by weight, based on the total weight of the hydrogel, said hydrogel is a viscoelastic gel having an elastic modulus which is measured at 20° C. of 0.05 kPa to 500 kPa and which is prepared by heating an aqueous suspension of a hydratable polymeric material to induce formation of a liquid sol, followed by cooling the sol to induce gelling, and

a plurality of coated active ingredient containing particles dispersed in said hydrogel,

wherein less than 0.1 wt % of the active ingredient is detectable in the hydrogel 1 month after the preparation of the composition,

at least one coating of said particles it triggered to disintegrate or dissolve by exposure to a particular pH range as a result of which the active ingredient is released, and

a dispenser pouch formed from flexible laminate sheets,

the hydrogel has a pH sufficiently different from the pH that triggers disintegration or dissolution of the at least one coating of the particles so as to require exposure of the pharmaceutical composition to an external stimulus in order to trigger disintegration or dissolution of the at least one coating of said particles and release of the active ingredient,

wherein the hydrogel comprises a buffer system, and

the at least one coating consists of: a) an ionic polymer; or b) non-ionic material selected from the group consisting of lipids, waxes, fats, fatty acids, mono-, di- and triglycerides, acetylated mono- and diglycerides, beeswax, and carnauba wax; and optionally c) at least one selected from the group consisting of pH modifiers, rheological modifiers, solvents, cross-linking agents, glidants, anti-tackifying agents, pigments, dyes, emulsifiers, stabilizers, flavours, sweeteners, and permeability enhancers.

15. The delivery system as claimed in claim 14 , wherein the pH of the hydrogel differs from the pH that triggers disintegration or dissolution of the at least one coating of the particles by at least 2.0.

16. The delivery system as claimed in claim 14 , wherein the at least one coating is an ionic polymer.

17. The delivery system as claimed in claim 14 , wherein the at least one coating is an enteric coating.

18. The delivery system as claimed in claim 14 , wherein the dispenser pouch is a stick pack.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2026
From: MAIER, HANS JÜRGEN
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 075682/0889 →
SECURITY INTEREST Recorded Dec 19, 2024
From: CATALENT CTS (KANSAS CITY), LLC; REDWOOD BIOSCIENCE, INC.; R.P. SCHERER TECHNOLOGIES, LLC; CATALENT WELLNESS, LLC; CATALENT PHARMA SOLUTIONS, INC.; CATALENT WELLNESS NEW JERSEY, LLC; CATALENT MARYLAND, INC.; CATALENT GREENVILLE, INC.; CATALENT MICRON TECHNOLOGIES, INC.; CATALENT SAN DIEGO, INC.; CATALENT WELLNESS VIRGINIA, LLC; CATALENT USA PACKAGING, LLC; CATALENT PHARMA SOLUTIONS, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 069743/0458 →